Edgewise Therapeutics, Inc. (EWTX)
| Market Cap | 852.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 49.26M |
| EPS (ttm) | -2.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,050 |
| Open | 15.99 |
| Previous Close | 15.89 |
| Day's Range | 15.99 - 17.42 |
| 52-Week Range | 13.60 - 40.49 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 31.75 (+83.5%) |
| Est. Earnings Date | Nov 8, 2021 |
About EWTX
Edgewise Therapeutics' vision is to improve the lives of patients and families suffering from rare muscle disorders by building the world’s leading muscle-focused, precision medicine company. In less than four years, we have matured into a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combi...
Financial Performance
Financial StatementsNews
Edgewise Therapeutics to Participate at SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treat...
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Individuals with Becker Muscular ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...
Edgewise Therapeutics Reports Second Quarter 2021 Financial Results
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...
Edgewise Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 11
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...
Edgewise Therapeutics to Present at the PPMD Annual Conference and the New Directions in Biology and Disease of Skele...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscl...
Losers Outnumber Gainers in Biotech IPOs This Year
Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.
Edgewise Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...
Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...
Edgewise Therapeutics Announces Publication of Data Demonstrating the Elevation of Fast but Not Slow Skeletal Muscle ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...
Edgewise Therapeutics Appoints Joanne Donovan, M.D., Ph.D., as Chief Medical Officer
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare musc...
2 Juicy Biotech Stocks to Consider Buying Right Now
They're both innovating in attractive areas where there's no competition on the radar.
Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option t...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Edgewise Therapeutics Announces Pricing of Initial Public Offering
Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announced today the ...
Rare disease biotech Edgewise Therapeutics files for a $100 million IPO
Edgewise Therapeutics, a Phase 1 biotech developing small molecule therapies for rare muscle disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Edgewise Therapeutics IPO Registration Document (S-1)
Edgewise Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.